Clinical Effect of Low Molecular Weight Heparin Sodium Combined with Magnesium Sulfate in the Treatment of Patients with Severe Preeclampsia.

Abstract

To investigate the effect of low molecular weight heparin sodium combined with magnesium sulfate in the treatment of patients with severe preeclampsia. An experimental study. The Department of Obstetrics and Gynecology, The Affiliated Hospital, North China University of Science and Technology, from April 2016 to July 2017. Patients with severe preeclampsia were randomly divided into observation group (52 cases) and control group (51 cases). In the control group, magnesium sulfate were used, but in observation group low molecular weight heparin sodium were added. After treatment of 7 days, serum TGF-β1, VCAM-1, ES levels and endothelial function markers of NO and ET-1 changes were compared between the two groups.The delivery status after treatment was observed in both groups. After treatment of 7 days, serum TGF-β1 and NO levels in the observation group were higher than those in control group (both p<0.001), and VCAM-1, ES, ET-1, ET-1/NO levels in observation group were lower than those in control group (all p<0.001). Among the patients who delivered live births, observation group had a longer delivery gestation age after treatment than that of control group (p=0.038); placental quality, body mass and 1 minute Apgar score of surviving newborns in observation group were all higher than those in control group (all p<0.001). Low molecular weight heparin sodium combined with magnesium sulfate may improve the.